The decision to treat with Otezla® has been made independently before inclusion in this study

Patient age ≥ 18 years

Existing diagnosis of active psoriatic arthritis

At least moderately severe psoriatic arthritis (Physician's Global Assessment (PGA) scale ≥ 2)

Insufficient response or intolerance to previous Disease-Modifying Anti-Rheumatic Drug (DMARD) treatment (disease modifying anti-rheumatic drugs)

A written informed consent statement by the patient permitting data collection, evaluation, storage and transfer

Study of Apremilast Use in Patients With Psoriatic Arthritic in Practice Conditions